Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system

A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients

(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941

A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure

Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604

PEARL-HF: Prevention of Hyperkalemia in Patients With Heart Failure Using a Novel Polymeric Potassium binder, RLY5016

Buysse, J., Huang, I., & Pitt, B. (2011) · Future Cardiology · doi:10.2217/fca.11.71 · Cited by 59

Safety of ACE inhibitor therapies in patients with chronic kidney disease

Sidorenkov, G. A., & Navis, G. J. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.951328 · Cited by 58

Epidemiology of hyperkalemia: an update

Kovesdy, C. P. (2016) · Kidney International Supplements · doi:10.1016/j.kisu.2016.01.002 · Cited by 59

A Physiologic-Based Approach to the Evaluation of a Patient With Hyperkalemia

Palmer, B. F. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.01.020 · Cited by 58

Investigation of aldosterone-synthase inhibition in rats

Ménard, J., Gonzalez, M.-F., Guyene, T.-T., & Bissery, A. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000226205.65442.f2 · Cited by 57

Hyperkalemia across the Continuum of Kidney Function

Palmer, B. F., & Clegg, D. J. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09340817 · Cited by 57

A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period

Formica, R. N., Friedman, A. L., Lorber, M. I., Smith, J. D., Eisen, T., & BIA, M. J. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfk058 · Cited by 57

Appropriateness of Spironolactone Prescribing in Heart Failure Patients: A Population-Based Study

Ko, D. T., Juurlink, D. N., Mamdani, M., You, J. J., Wang, J. T., Donovan, L. R., & Tu, J. V. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.01.003 · Cited by 59

Long-Term Effects of Patiromer for Hyperkalaemia Treatment in Patients with Mild Heart Failure and Diabetic Nephropathy on Angiotensin-Converting Enzymes/Angiotensin Receptor Blockers: Results from AMETHYST-DN

Pitt, B., Bakris, G. L., Weir, M. R., Freeman, M. W., Lainščak, M., Mayo, M. R., Garza, D., Zawadzki, R., Berman, L., & Bushinsky, D. A. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12292 · Cited by 55

Heart Failure: A Class Review of Pharmacotherapy.

Shah, A. A., Gandhi, D., Srivastava, S., Shah, K. J., & Mansukhani, R. P. (2017) · PubMed Central · Cited by 55

Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials)

Tromp, J., ter Maaten, J. M., Damman, K., O’Connor, C. M., Metra, M., Dittrich, H. C., Ponikowski, P. P., Teerlink, J. R., Cotter, G., Davison, B. A., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.09.038 · Cited by 55

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy

Orena, S., Maurer, T. S., She, L., Eudy, R. J., Bernardo, V., Dash, D., Loria, P. M., Banker, M. E., Tugnait, M., Okerberg, C. V., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00115 · Cited by 54

Management of Hyperkalemia With Insulin and Glucose: Pearls for the Emergency Clinician

Moussavi, K., Fitter, S., Gabrielson, S. W., Koyfman, A., & Long, B. (2019) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2019.03.043 · Cited by 52

Frequency and Predictors of Hyperkalemia in Patients ≥60 Years of Age With Heart Failure Undergoing Intense Medical Therapy

Muzzarelli, S., Maeder, M. T., Toggweiler, S., Rickli, H., Nietlispach, F., Julius, B. K., Burkard, T., Pfisterer, M. E., & Rocca, H. B. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.10.027 · Cited by 54

The Management of Hyperkalemia in Patients with Cardiovascular Disease

Khanna, A., & White, W. B. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.10.028 · Cited by 52

Potassium: friend or foe?

Rodan, A. R. (2016) · Pediatric Nephrology · doi:10.1007/s00467-016-3411-8 · Cited by 53

Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients

Kovesdy, C. P., Rowan, C. G., Conrad, A., Spiegel, D. M., Fogli, J., Oestreicher, N., Connaire, J. J., & Winkelmayer­, W. C. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.10.020 · Cited by 51

Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias

Jøns, C., Zheng, C., Winsløw, U., Danielsen, E. M., Sakthivel, T., Frandsen, E. A., Saffi, H., Vakilzadeh-Hashemi, S. S., Haugan, K., Bruun, N. E., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2509542 · Cited by 50

Clinical factors associated with hyperkalemia in patients with congestive heart failure1

Ramadan, F. H., Masoodi, N. A., & El-Solh, A. (2005) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2005.00638.x · Cited by 49

Potassium binders for chronic hyperkalaemia in people with chronic kidney disease

Natale, P., Palmer, S. C., Ruospo, M., Saglimbene, V. M., & Strippoli, G. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013165.pub2 · Cited by 48

Mechanisms of Impaired Potassium Handling With Dual Renin-Angiotensin-Aldosterone Blockade in Chronic Kidney Disease

Preston, R. A., Afshartous, D. R., Garg, D. C., Medrano, S., Alonso, A. B., & Rodríguez, R. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.125252 · Cited by 48

Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril

Johnson, E. S., Weinstein, J., Thorp, M. L., Platt, R. W., Petrik, A. F., Yang, X., Anderson, S., & Smith, D. H. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1923 · Cited by 47

Serum Potassium Levels and Risk of Sudden Cardiac Death Among Patients With Chronic Kidney Disease and Significant Coronary Artery Disease

Pun, P. H., Goldstein, B. A., Gallis, J. A., Middleton, J. P., & Svetkey, L. P. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.07.001 · Cited by 47

Potassium physiology from Archean to Holocene: A higher-plant perspective

Britto, D. T., Coskun, D., & Kronzucker, H. J. (2021) · Journal of Plant Physiology · doi:10.1016/j.jplph.2021.153432 · Cited by 48

Clinical Experience with Spironolactone in Pediatrics

Buck, M. L. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e618 · Cited by 47

Drug Interactions—A Review

Manzi, S. F., & Shannon, M. W. (2005) · Clinical Pediatric Emergency Medicine · doi:10.1016/j.cpem.2005.04.006 · Cited by 46

Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice

Nicola, L. D., Lullo, L. D., Paoletti, E., Cupisti, A., & Bianchi, S. (2018) · Journal of Nephrology · doi:10.1007/s40620-018-0502-6 · Cited by 49

Hyperkalemia Associated With Inhibitors of the Renin-Angiotensin-Aldosterone System

Desai, A. S. (2008) · Circulation · doi:10.1161/circulationaha.108.807917 · Cited by 46

Disorders of Potassium Balance

Mount, D. B., & Zandi‐Nejad, K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10017-x · Cited by 45

Effects of Hyperkalaemia and Non-Adherence to Renin–Angiotensin–Aldosterone System Inhibitor Therapy in Patients with Heart Failure in Italy: A Propensity-Matched Study

Volterrani, M., Perrone, V., Sangiorgi, D., Giacomini, E., Iellamo, F., Esposti, L. D., & on the behalf of a LHUs Study Group (see Appendix) (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2024 · Cited by 45

A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers

Hline, S. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5176 · Cited by 46

Beneficial Effects on Arterial Stiffness and Pulse-Wave Reflection of Combined Enalapril and Candesartan in Chronic Kidney Disease - A Randomized Trial

Frimodt‐Møller, M., Kamper, A., Strandgaard, S., Kreiner, S., & Nielsen, A. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041757 · Cited by 45

Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors

Weir, M. R., Bushinsky, D. A., Benton, W. W., Woods, S. D., Mayo, M. R., Arthur, S. P., Pitt, B., & Bakris, G. L. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.11.011 · Cited by 45

Hyperkalemia treatment standard

Palmer, B. F., & Clegg, D. J. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae056 · Cited by 43

Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure

Vardeny, O., Cavallari, L. H., Claggett, B. L., Desai, A. S., Anand, I. S., Rossignol, P., Zannad, F. M., Pitt, B., & Solomon, S. D. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.113.000530 · Cited by 44

Global cardiovascular protection in chronic kidney disease

Ruiz‐Hurtado, G., Sarafidis, P. A., Fernández‐Alfonso, M. S., Waeber, B., & Ruilope, L. M. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.48 · Cited by 44

Epidemiología de la hiperpotasemia en la enfermedad renal crónica

Belmar, L., Galabia, E. R., da Silva, J. B., González, M. B., Fresnedo, G. F., Haces, C. P., Fontanet, R. P., Ruiz, J. C., & de Francisco, Á. L. M. (2019) · Nefrología · doi:10.1016/j.nefro.2018.11.011 · Cited by 43

Epidemiology of hyperkalemia in chronic kidney disease

Belmar, L., Galabia, E. R., da Silva, J. B., González, M. B., Fresnedo, G. F., Haces, C. P., Fontanet, R. P., Ruiz, J. C., & de Francisco, Á. L. M. (2019) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2018.11.014 · Cited by 43

Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality

Beusekamp, J. C., Tromp, J., Cleland, J. G. F., Givertz, M. M., Metra, M., O’Connor, C. M., Teerlink, J. R., Ponikowski, P. P., Ouwerkerk, W., van Veldhuisen, D. J., et al. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.07.010 · Cited by 43

Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis

Chrysant, S. G., Murray, A. V., Hoppe, U. C., Dattani, D., PATEL, S. N., Hsu, H., & Zhang, J. Y. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x280581 · Cited by 43

Preventing and treating kidney disease in patients with type 2 diabetes

Delanaye, P., & Scheen, A. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1551362 · Cited by 42

Optimal Antagonism of the Renin-Angiotensin-Aldosterone System

Werner, C. M., Pöss, J., & Böhm, M. (2010) · Drugs · doi:10.2165/11537910-000000000-00000 · Cited by 41

Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price?

Philibert, D., & Cattran, D. C. (2008) · Nature Reviews Nephrology · doi:10.1038/ncpneph0915 · Cited by 41

Diuretic effects of sodium–glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure

Takeuchi, T., Dohi, K., Omori, T., Moriwaki, K., Sato, Y., Nakamori, S., Fujimoto, N., Fujii, E., Yamada, N., & Ito, M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.072 · Cited by 40

Therapeutic Approach to Electrolyte Emergencies

Schaer, M. (2008) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2008.01.012 · Cited by 40

SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study

Fu, E. L., Wexler, D. J., CROMER, S. J., Bykov, K., Paik, J. M., & Patorno, E. (2024) · BMJ · doi:10.1136/bmj-2023-078483 · Cited by 40

2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II—treatments of hypertension

Shin, J., Park, J. B., Kim, K., Kim, J. H., Yang, D. H., Pyun, W. B., Kim, Y. G., Kim, G., & Chae, S. C. (2015) · Clinical Hypertension · doi:10.1186/s40885-014-0013-2 · Cited by 40

Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus

Dande, R. R., Peev, V., Altintas, M. M., & Reiser, J. (2017) · Journal of Diabetes Research · doi:10.1155/2017/3232848 · Cited by 39

Application of Direct Renin Inhibition to Chronic Kidney Disease

Mende, C. W. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6232-1 · Cited by 38

Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition

Alfie, J., Aparicio, L. S., & D., W. (2011) · Reviews on Recent Clinical Trials · doi:10.2174/157488711795177912 · Cited by 37

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics

Weir, M. R., Mayo, M. R., Garza, D., Arthur, S. A., Berman, L., Bushinsky, D. A., Wilson, D. J., & Epstein, M. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001278 · Cited by 37

Current treatment and unmet needs of hyperkalaemia in the emergency department

Rafique, Z., Chouihed, T., Mebazaa, A., & Peacock, W. F. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suy029 · Cited by 37

Effect of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on the Frequency of Post-Cardiothoracic Surgery Atrial Fibrillation

Coleman, C. I., Makanji, S. S., Kluger, J., & White, C. M. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h583 · Cited by 37

Adverse drug reactions related to hospital admission in Slovak elderly patients

Wawruch, M., Zikavska, M., Wsólová, L., Kuželová, M., Kahayova, K., Strateny, K., & Kristová, V. (2008) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2008.01.004 · Cited by 36

Advances in treatment of hyperkalemia in chronic kidney disease

Sarafidis, P. A., Georgianos, P. I., & Bakris, G. L. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1083977 · Cited by 36

Regulation of Potassium Homeostasis in CKD

DuBose, T. D. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.06.002 · Cited by 36

DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients

Karaboyas, A., Xu, H., Morgenstern, H., Locatelli, F., Jadoul, M. Y., Nitta, K., Dasgupta, I., Tentori, F., Port, F. K., & Robinson, B. M. (2018) · Kidney International · doi:10.1016/j.kint.2018.03.013 · Cited by 36

Activation of mTORC1 in Collecting Ducts Causes Hyperkalemia

Chen, Z., Dong, H., Jia, C., Song, Q., Chen, J., Zhang, Y., Lai, P., Fan, X., Zhou, X., Liu, M., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013030225 · Cited by 35

New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors

Tamargo, J. L., Caballero, R., & Delpón, E. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6767-5 · Cited by 37

Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trial

Ferreira, J. P., Claggett, B. L., Liu, J., Desai, A. S., Pfeffer, M. A., Anand, I. S., van Veldhuisen, D. J., Køber, L., Cleland, J. G. F., Rouleau, J. L., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2134 · Cited by 36

Taking the Kale out of Hyperkalemia: Plant Foods and Serum Potassium in Patients With Kidney Disease

Babich, J. S., Kalantar‐Zadeh, K., & Joshi, S. (2022) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2022.01.013 · Cited by 35

Identification and Management of Albuminuria in the Primary Care Setting

Kuritzky, L., Toto, R. D., & Buren, P. N. V. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00424.x · Cited by 37

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers

Lesko, L. J., Offman, E. M., Brew, C. T., Garza, D., Benton, W. W., Mayo, M. R., Romero, A., Mond, C. D., & Weir, M. R. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417691135 · Cited by 35

Let Them Eat Healthy: Can Emerging Potassium Binders Help Overcome Dietary Potassium Restrictions in Chronic Kidney Disease?

Sussman, E. J., Singh, B. P., Clegg, D. J., Palmer, B. F., & Kalantar‐Zadeh, K. (2020) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2020.01.022 · Cited by 34

Mineralocorticoid Receptor Blockers and Chronic Kidney Disease

Jain, G., Campbell, R. C., & Warnock, D. G. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01340209 · Cited by 33

The Renin-Angiotensin-Aldosterone System in Renal and Cardiovascular Disease and the Effects of its Pharmacological Blockade

Heras, M. M., Rodríguez, N. D. C., & Navarro‐González, J. F. (2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000171 · Cited by 35

Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study

Yarows, S. A., Oparil, S., PATEL, S. N., Fang, H., & Zhang, J. Y. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0123-x · Cited by 34

Laboratory Evaluation of Potassium and Creatinine Among Ambulatory Patients Prescribed Spironolactone: Are We Monitoring for Hyperkalemia?

Raebel, M. A., McClure, D. L., Chan, K. A., Simon, S. R., Feldstein, A. C., Lafata, J. E., Andrade, S. E., Gunter, M. J., Nelson, W. W., Roblin, D. W., et al. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h520 · Cited by 32

Approach to Fluid and Electrolyte Disorders and Acid-Base Problems

Palmer, B. F. (2008) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2008.01.004 · Cited by 32

Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: Insights from the HEAAL study

Rossignol, P., Dobre, D., Gregory, D., Massaro, J. M., Kiernan, M., Konstam, M. A., & Zannad, F. M. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.02.034 · Cited by 31

Aprocitentan and the endothelin system in resistant hypertension

Clozel, M. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2022-0010 · Cited by 31

Predicting Adverse Events During Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial

Kiernan, M. S., Wentworth, D. N., Francis, G. S., Martínez, F. A., Dickstein, K., Michel Komajda, N., Zannad, F. M., Neaton, J. D., & Konstam, M. A. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs145 · Cited by 31

Potential side effects of renin inhibitors – mechanisms based on comparison with other renin–angiotensin blockers

Cheng, H., & Harris, R. C. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.5.631 · Cited by 31

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases

Liu, Q., Cui, Z., Deng, C., Yang, C., & Tao, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1485190 · Cited by 30

Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator

Erlandsson, F., Albayaty, M., Chialda, L., Ericsson, H., Amilon, C., Nelander, K., Jansson‐Löfmark, R., Wernevik, L. C., Kjaer, M., Bamberg, K., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13562 · Cited by 30

Barriers to guideline mandated renin–angiotensin inhibitor use: focus on hyperkalaemia

Vijayakumar, S., Butler, J., & Bakris, G. L. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suy030 · Cited by 31

Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases

Amir, O., Hassan, Y., Sarriff, A., Awaisu, A., Aziz, N. A., & Ismail, O. (2009) · Pharmacy World & Science · doi:10.1007/s11096-009-9288-x · Cited by 30

Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives

Loughlin, J. E., Seeger, J. D., Eng, P. M., Foegh, M. L., Clifford, C. R., Cutone, J. A., & Walker, A. M. (2008) · Contraception · doi:10.1016/j.contraception.2008.06.012 · Cited by 30

Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions

Henz, S., Maeder, M. T., Huber, S., Schmid, M., Loher, M., & Fehr, T. H. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn380 · Cited by 30

Life‐threatening drug‐associated hyperkalemia: a retrospective study from laboratory signals

Noïze, P., Bagheri, H., Durrieu, G., Haramburu, F., Moore, N. D., Giraud, P., Galinier, M., Pourrat, J. P., & Montastruc, J. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2128 · Cited by 29

Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia

Nakayama, Y., Ueda, K., Yamagishi, S., Sugiyama, M., Yoshida, C., Kurokawa, Y., Nakamura, N., Moriyama, T., Kodama, G., Minezaki, T., et al. (2017) · Clinical and Experimental Nephrology · doi:10.1007/s10157-017-1412-y · Cited by 29

Aldosterone antagonists in the treatment of heart failure

Marcy, T. R., & Ripley, T. L. (2005) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050041 · Cited by 30

Effect of furosemide on left ventricular mass in non-dialysis chronic kidney disease patients: a randomized controlled trial

Zamboli, P., Nicola, L. D., Minutolo, R., Chiodini, P., Crivaro, M., Tassinario, S., Bellizzi, V., & Conte, G. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq565 · Cited by 29

Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure

Grodin, J. L. (2016) · Current Heart Failure Reports · doi:10.1007/s11897-016-0295-7 · Cited by 28

Real-world management of hyperkalemia with patiromer among United States Veterans

Kovesdy, C. P., Gosmanova, E. O., Woods, S. D., Fogli, J., Rowan, C. G., Hansen, J. L., & Sauer, B. C. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2019.1706920 · Cited by 28

Poly(methyl methacrylate)s with Pendant Calixpyrroles and Crown Ethers: Polymeric Extractants for Potassium Halides

Aydogan, A., Coady, D. J., Kim, S. K., Akar, A., Bielawski, C. W., Márquez, M., & Sessler, J. L. (2008) · Angewandte Chemie · doi:10.1002/ange.200803970 · Cited by 28

Beta-Blockers, Trimethoprim-Sulfamethoxazole, and the Risk of Hyperkalemia Requiring Hospitalization in the Elderly

Weir, M. A., Juurlink, D. N., Gomes, T., Mamdani, M., Hackam, D. G., Jain, A. K., & Garg, A. X. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01970310 · Cited by 28

Renal dysfunction in heart failure patients: what is the evidence?

SALTZMAN, H. E., Sharma, K., Mather, P. J., Rubin, S., Adams, S., & Whellan, D. J. (2007) · Heart Failure Reviews · doi:10.1007/s10741-007-9006-5 · Cited by 28

Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?

Azizi, M., & Ménard, J. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6380-6 · Cited by 28

Metabolic complications associated with use of thiazide diuretics

Palmer, B. F., & Naderi, A. S. A. (2007) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2007.07.004 · Cited by 27

Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals

Ramı́rez, E., Rossignoli, T., Campos, A. J., Muñoz, R., Zegarra, C., Tong, H. Y., Medrano, N., Borobia, A. M., Carcas, A. J., & Frías, J. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1303-9 · Cited by 27

New options for the management of chronic hyperkalemia

Fried, L. F., Kovesdy, C. P., & Palmer, B. F. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.09.001 · Cited by 29

Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?

Silvariño, R., Rios, P. G., Baldovinos, G., Chichet, M. A., Perg, N., Solá, L., Saona, G., Souza, N. D., Lamadrid, V., & Gadola, L. (2019) · The Nephron journals/Nephron journals · doi:10.1159/000500925 · Cited by 27

Pharmacologic Treatment of Chronic Hyperkalemia in Patients with Chronic Kidney Disease

Kim, G. (2019) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2019.17.1.1 · Cited by 27

Patiromer: a clinical review

Montaperto, A. G., Gandhi, M. A., Gashlin, L. Z., & Symoniak, M. R. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1106935 · Cited by 26

Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study

Espinel, E., Joven, J., Nuñez-Gil, I. J., Suñé, P., Renedo, B., Fort, J., & Serón, D. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-306 · Cited by 26

Blood Pressure and Serum Potassium Levels in Hypertensive Patients Receiving or Not Receiving Antihypertensive Treatment

Pikilidou, M. I., Lasaridis, A. N., Sarafidis, P. A., Tziolas, I. M., Zebekakis, P. E., Dombros, N., & Giannoulis, E. (2007) · Clinical and Experimental Hypertension · doi:10.1080/10641960701744103 · Cited by 26

Sodium Zirconium Cyclosilicate ( ZS ‐9): A Novel Agent for the Treatment of Hyperkalemia

Linder, K. E., Krawczynski, M. A., & Laskey, D. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1797 · Cited by 26

Chronic Hyperkalemia in Cardiorenal Patients: Risk Factors, Diagnosis, and New Treatment Options

Lullo, L. D., Ronco, C., Granata, A. R. M., Paoletti, E., Bàrbera, V., Cozzolino, M. G., Ravera, M., Fusaro, M., & Bellasi, A. (2018) · Cardiorenal Medicine · doi:10.1159/000493395 · Cited by 27

Risk Factors Associated with a High Velocity of the Development of Hyperkalaemia in Hospitalised Patients

Indermitte, J., Burkolter, S., Drewe, J., hl, S. K. H., & Hersberger, K. E. (2007) · Drug Safety · doi:10.2165/00002018-200730010-00007 · Cited by 26

Systematic Review Of Hyperkalemia Due To Angiotensin Enzyme Converting Inhibitors

Aggarwal, S., Topaloglu, H., & Kumar, S. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.898

Systematic Review of Burden of Hyperkalemia due to Angiotensin Enzyme Converting Inhibitors

Aggarwal, S., Kumar, S., & Topaloglu, H. (2016) · Value in Health · doi:10.1016/j.jval.2016.03.082

Hyperkalemia and Inhibitors of the Renin–Angiotensin–Aldosterone System

Segal, A. Z. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412023512321 · Cited by 2

Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Closer Look at Hyperkalemia

Chung, S., & Park, C. W. (2011) · The Korean Journal of Internal Medicine

Hyperkalemia Associated with Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Raebel, M. A. (2011) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00258.x · Cited by 190